These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 1418306)

  • 1. Pharmacologic evaluation of SCH-39166, A-69024, NO-0756, and SCH-23390 in neonatal-6-OHDA-lesioned rats. Further evidence that self-mutilatory behavior induced by L-dopa is related to D1 dopamine receptors.
    Criswell HE; Mueller RA; Breese GR
    Neuropsychopharmacology; 1992 Sep; 7(2):95-103. PubMed ID: 1418306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological evaluation of SCH-12679: evidence for an in vivo antagonism of D1-dopamine receptors.
    Breese GR; Criswell HE; McQuade RD; Iorio LC; Mueller RA
    J Pharmacol Exp Ther; 1990 Feb; 252(2):558-67. PubMed ID: 1968972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence that D-1 dopamine receptors contribute to the supersensitive behavioral responses induced by L-dihydroxyphenylalanine in rats treated neonatally with 6-hydroxydopamine.
    Breese GR; Baumeister A; Napier TC; Frye GD; Mueller RA
    J Pharmacol Exp Ther; 1985 Nov; 235(2):287-95. PubMed ID: 3932640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dopamine agonist-induced locomotor activity in rats treated with 6-hydroxydopamine at differing ages: functional supersensitivity of D-1 dopamine receptors in neonatally lesioned rats.
    Breese GR; Napier TC; Mueller RA
    J Pharmacol Exp Ther; 1985 Aug; 234(2):447-55. PubMed ID: 3926987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Self-injurious behavior and dopaminergic neuron system in neonatal 6-hydroxydopamine-lesioned rat: 2. Intracerebral microinjection of dopamine agonists and antagonists.
    Okamura H; Murakami T; Yokoyama C; Nakamura T; Ibata Y
    J Pharmacol Exp Ther; 1997 Feb; 280(2):1031-7. PubMed ID: 9023320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence for involvement of brain dopamine and other mechanisms in the behavioral action of the N-methyl-D-aspartic acid antagonist MK-801 in control and 6-hydroxydopamine-lesioned rats.
    Criswell HE; Johnson KB; Mueller RA; Breese GR
    J Pharmacol Exp Ther; 1993 May; 265(2):1001-10. PubMed ID: 8098756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Motor stimulant effects of the adenosine A2A receptor antagonist SCH 58261 do not develop tolerance after repeated treatments in 6-hydroxydopamine-lesioned rats.
    Pinna A; Fenu S; Morelli M
    Synapse; 2001 Mar; 39(3):233-8. PubMed ID: 11284438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of D1/D2 dopamine receptor synergisms following repeated administration of D1 or D2 receptor selective antagonists: electrophysiological and behavioral studies.
    Hu XT; White FJ
    Synapse; 1994 May; 17(1):43-61. PubMed ID: 7913772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The atypical dopamine D1 receptor agonist SKF 83959 induces striatal Fos expression in rats.
    Wirtshafter D; Osborn CV
    Eur J Pharmacol; 2005 Dec; 528(1-3):88-94. PubMed ID: 16324697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Behavioral differences between neonatal and adult 6-hydroxydopamine-treated rats to dopamine agonists: relevance to neurological symptoms in clinical syndromes with reduced brain dopamine.
    Breese GR; Baumeister AA; McCown TJ; Emerick SG; Frye GD; Crotty K; Mueller RA
    J Pharmacol Exp Ther; 1984 Nov; 231(2):343-54. PubMed ID: 6149306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective dopamine antagonist pretreatment on the antiparkinsonian effects of benzazepine D1 dopamine agonists in rodent and primate models of Parkinson's disease--the differential effects of D1 dopamine antagonists in the primate.
    Gnanalingham KK; Hunter AJ; Jenner P; Marsden CD
    Psychopharmacology (Berl); 1995 Feb; 117(4):403-12. PubMed ID: 7604140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of uncoupling between D1- and D2-mediated motor behavior in rats depleted of dopamine as neonates.
    Byrnes EM; Bruno JP
    Dev Psychobiol; 1994 Sep; 27(6):409-24. PubMed ID: 8001729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Electrophysiological effects of SKF 38393 in rats with reserpine treatment and 6-hydroxydopamine-induced nigrostriatal lesions reveal two types of plasticity in D1 dopamine receptor modulation of basal ganglia output.
    Huang KX; Walters JR
    J Pharmacol Exp Ther; 1994 Dec; 271(3):1434-43. PubMed ID: 7996456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Supersensitized D1 receptors mediate enhanced oral activity after neonatal 6-OHDA.
    Kostrzewa RM; Gong L
    Pharmacol Biochem Behav; 1991 Jul; 39(3):677-82. PubMed ID: 1686103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Augmented sensitivity of D1-dopamine receptors in lateral but not medial striatum after 6-hydroxydopamine-induced lesions in the neonatal rat.
    Simson PE; Johnson KB; Jurevics HA; Criswell HE; Napier TC; Duncan GE; Mueller RA; Breese GR
    J Pharmacol Exp Ther; 1992 Dec; 263(3):1454-63. PubMed ID: 1361576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the D1-dopamine agonists SKF-38393 and A-68930 in neonatal 6-hydroxydopamine-lesioned rats: behavioral effects and induction of c-fos-like immunoreactivity.
    Johnson KB; Criswell HE; Jensen KF; Simson PE; Mueller RA; Breese GR
    J Pharmacol Exp Ther; 1992 Aug; 262(2):855-65. PubMed ID: 1354257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dopamine supersensitivity and D1/D2 synergism are unrelated to changes in striatal receptor density.
    LaHoste GJ; Marshall JF
    Synapse; 1992 Sep; 12(1):14-26. PubMed ID: 1357762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Behavioral and neurochemical responses to haloperidol and SCH-23390 in rats treated neonatally or as adults with 6-hydroxydopamine.
    Duncan GE; Criswell HE; McCown TJ; Paul IA; Mueller RA; Breese GR
    J Pharmacol Exp Ther; 1987 Dec; 243(3):1027-34. PubMed ID: 3121842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dopaminergic functional supersensitivity: effects of chronic L-dopa and carbidopa treatment in an animal model of Parkinson's disease.
    Hossain MA; Weiner N
    J Pharmacol Exp Ther; 1993 Dec; 267(3):1105-11. PubMed ID: 8263772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. D1 dopamine receptor-mediated substance P depletion in the striatonigral neurons of rats subjected to neonatal dopaminergic denervation: implications for self-injurious behavior.
    Sivam SP
    Brain Res; 1989 Oct; 500(1-2):119-30. PubMed ID: 2481560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.